Answers are grounded in this paper and cite their sources.
Background: Hepatic enzymes are perturbed in liver cirrhosis, reflecting hepatocyte damage, dysfunction and disease stage, and thus play an important role in diagnosis and prognostic stratification. Aims of the study: To assess the levels of hepatic enzymes and their relationship in the severity of the disease in patients with liver cirrhosis. Methodology: This case-control study enrolled 70 patients with liver cirrhosis and 35 healthy controls from April 2025 to February 2026 in a specialized hepatology unit in Iraq. Clinical, laboratory and imaging confirmed the diagnosis, with severity assessed by the Child–Pugh score. Five millilitres of venous blood were drawn, centrifuged and serum frozen at −20°C. Serum levels of hepatic enzymes (ALT, AST, ALP), bilirubin and albumin were determined using spectrophotometric and enzymatic methods. Sociodemographic and clinical data were recorded. Result: No significant differences were observed between cirrhosis patients and controls in age, gender, BMI, smoking, or alcohol intake. However, hepatic biomarkers were significantly altered in patients, with elevated ALT, AST, ALP, and bilirubin, and reduced albumin (p < 0.001). These markers progressively worsened with disease severity. ALT, AST, ALP, and bilirubin had positive correlations and albumin had a negative correlation. AST, bilirubin and albumin independently predicted severe cirrhosis on multivariate analysis. Conclusions: Elevation of hepatic enzymes and bilirubin and decrease of albumin with severity of cirrhosis reflect hepatocellular injury, decreased detoxification and protein synthesis and can be used as good indicators of disease progression and outcome.
No takes yet. Share an insight, caveat, or question.
Hasan et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: